Updated Guidelines for Treatment of Advanced HER2-Positive Breast Cancer 更新版HER2阳性乳腺癌治疗指南 William J. Gradishar, MD 上一次于2014年更新之后,建议基本上无变化。 主办机构:美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)。 ...
patients ORR was 43.8%. Grade ≥3 treatment-emergent AEs occurred in 61.5% of patients, with decreased neutrophil count and anemia being most common. Of note, five patients on this trial developed interstitial lung disease re...
use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. ...
2.NCCN Clinical Practice Guidelines in Oncology. January 27, 2023. Accessed February 1, 2023. https://bit.ly/3HqLZ9t 3.Puma Biotechnology’s NERLYNX® included in NCCN Clinical Practice Guidelines for the treatment of breast cancer with a HER2 mutation. News release. Puma Biotechnology. Febr...
Adjuvant Breast Cancer Herceptin is approved for the treatment of adults with early-stage breast cancer that isHumanEpidermal growth factorReceptor2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into th...
[32]《NCCN Guidelines Version 4.2022 Breast Cancer》 [33]Zagouri F, Zoumpourlis P, Le Rhun E, et al. Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. Cancer Treat Rev. 2020 Aug;88:102046....
JackischC.(Offenbach)Jackisch, C. Treatment Options in ErbB2 (HER2)-Overexpressing Breast Cancer. Breast Care (2008) 3(1): 1-5Treatment Options in ErbB2 (HER2)-Overexpressing Breast Cancer. Jackisch C. Breast Care (Basel) . 2008
2024年研究新进展一览,胃癌治疗迎来新突破。 胃癌是一种异质性和侵袭性极高的恶性肿瘤,多数患者确诊时已处于进展期,预后差。全身治疗是目前晚期胃癌最主要的治疗方式,人表皮生长因子受体2(HER2)是胃癌的重要治疗靶点,其研究进展备受学界关注。新一代抗体偶联药物(ADC)为HER2阳性晚期胃癌治疗开辟了新的前景。此外,随着...
In spite of the fact that overall survival has significantly improved accordingly, resistance to treatment remains a challenge in HER2-positive breast cancer. The introduction of new agents has created awareness regarding new potential specific adverse events, and consequently, their increasing application...
[1]NCCN Clinical Practice Guidelines in Oncology:Breast Cancer(Version 1.2021)[EB/OL].Plymouth Meeting:NCCN2021[2021-01-15].Available at:http://www.nccn.org.[Accessed 15 Jan,2021]. [2]Chinese Society of Clinical Oncology CSCO.Breast ...